If you're interested in broad exposure to the Healthcare - Biotech segment of the equity market, look no further than the Invesco Biotechnology & Genome ETF (PBE), a passively managed exchange traded fund launched on 06/23/2005. Passively managed ETFs are becoming increasingly popular with institutional as well as retail investors due to their low cost, transparency, flexibility and tax efficiency. They are excellent vehicles for long term investors. Additionally, sector ETFs offer convenient ways to gain low risk and diversified exposure to a broad group of companies in particular sectors. Healthcare - Biotech is one of the 16 broad Zacks sectors within the Zacks Industry classification. It is currently ranked 4, placing it in top 25%. The fund is sponsored by Invesco. It has amassed assets over $239.91 million, making it one of the average sized ETFs attempting to match the performance of the Healthcare - Biotech segment of the equity market. PBE seeks to match the performance of the Dynamic Biotechnology & Genome Intellidex Index before fees and expenses. The Dynamic Biotech & Genome Intellidex Index seeks to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including price momentum, earnings momentum, quality, management action, and value. When considering an ETF's total return, expense ratios are an important factor, and cheaper funds can significantly outperform their more expensive counterparts in the long term if all other factors remain equal. Annual operating expenses for this ETF are 0.58%, making it on par with most peer products in the space. It has a 12-month trailing dividend yield of 0.01%. Even though ETFs offer diversified exposure that minimizes single stock risk, investors should also look at the actual holdings inside the fund. This ETF has heaviest allocation in the Healthcare sector--about 99.80% of the portfolio. Looking at individual holdings, Gilead Sciences Inc (GILD) accounts for about 6.79% of total assets, followed by Amgen Inc (AMGN) and Incyte Corp (INCY). The top 10 holdings account for about 47.02% of total assets under management. Year-to-date, the Invesco Biotechnology & Genome ETF has lost about -0.40% so far, and is up roughly 1.66% over the last 12 months (as of 03/24/2025). PBE has traded between $59.62 and $72.24 in this past 52-week period. The ETF has a beta of 0.80 and standard deviation of 22.02% for the trailing three-year period, making it a high risk choice in the space. With about 32 holdings, it has more concentrated exposure than peers. Invesco Biotechnology & Genome ETF holds a Zacks ETF Rank of 2 (Buy), which is based on expected asset class return, expense ratio, and momentum, among other factors. Because of this, PBE is an excellent option for investors seeking exposure to the Health Care ETFs segment of the market. There are other additional ETFs in the space that investors could consider as well. SPDR S&P Biotech ETF (XBI) tracks S&P Biotechnology Select Industry Index and the iShares Biotechnology ETF (IBB) tracks Nasdaq Biotechnology Index. SPDR S&P Biotech ETF has $5.66 billion in assets, iShares Biotechnology ETF has $6.07 billion. XBI has an expense ratio of 0.35% and IBB charges 0.45%. To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report. Invesco Biotechnology & Genome ETF (PBE): ETF Research Reports Amgen Inc. (AMGN) : Free Stock Analysis Report Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report Incyte Corporation (INCY) : Free Stock Analysis Report iShares Biotechnology ETF (IBB): ETF Research Reports SPDR S&P Biotech ETF (XBI): ETF Research Reports This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today

This article discusses the Invesco Biotechnology & Genome ETF (PBE), a passively managed ETF launched on June 23, 2005, which seeks to match the performance of the Dynamic Biotechnology & Genome Intellidex Index. The ETF has a market value of $239.91 million and is sponsored by Invesco. It has an expense ratio of 0.58% and a 12-month trailing dividend yield of 0.01%. The ETF is heavily weighted towards the Healthcare sector, with Gilead Sciences Inc (GILD), Amgen Inc (AMGN), and Incyte Corp (INCY) being the top holdings. The article also mentions other biotech-focused ETFs like SPDR S&P Biotech ETF and iShares Biotechnology ETF.